SLC12A5 and prostate cancer: We further performed survival analysis using TCGA datasets and found that the high expression of SLC12A5 was significantly associated with poor overall survival [hazard ratio (HR) = 5.060, 95% confidence interval (CI) = 1.464–17.49, P = 0.010)] and recurrence-free survival (HR = 1.855, 95% CI = 1.058–3.253, P = 0.031) in patients with prostate cancer (Fig. 1G, H).